Trials / Unknown
UnknownNCT05275062
Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 6 (estimated)
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a open-label, single center to determine the efficacy and safety of IM92 CAR-T cells in Patients With advanced gastric/esophagogastric combination adenocarcinoma that has failed at least second-line therapy and advanced pancreatic cancer that has failed at least first-line therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IM92 CAR-T cells | 2.5×10\^8 CAR-T cells |
Timeline
- Start date
- 2022-02-15
- Primary completion
- 2024-03-01
- Completion
- 2024-05-01
- First posted
- 2022-03-11
- Last updated
- 2022-03-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05275062. Inclusion in this directory is not an endorsement.